In order to evaluate the possible role of lisuride as an alternative to bromocriptine therapy for hyperprolactinemic amenorrhea and infertility, we performed a prospective, comparative study in 62 patients with idiopathic hyperprolactinemia or
with
prolactin-secreting pituitary tumor. The patients were allocated randomly into two groups, each consisting of 31 patients: by the double-blind procedure, one group received lisuride for 24 weeks or until she was pregnant whereas the other was
treated
with bromoccriptine. By this treatment, serum prolactin levels were normalized in twenty-two (71%) of 31 patients in the lisurde group and twenty-four (77%) of 31 patients in the bromocriptine group. Restoration of menses was achieved in eleven
(65%) of
17 patients within 14.0±2.4 weeks [±SEM] in the lisuride group (final dosage, 0.41±0.05 mg/d) and in thirteen (65%) of 20 patients within 12.0±2.1 weeks in the bromocriptine group (final dosage, 5.13±0.50 mg/d). And, pregnancies were
confirmed
in
ten (72%) of 14 patients within 11.6±1.9 weeks in the lisuride group (final dosage, 0.35±0.06 mg/d) and in nine (82%) of 11 patients within 11.6±1.6 weeks in the bromocriptine group (final dosage, 4.50±0.88 mg/d). Side effects, consisting of
nausea,
drowsiness, headache, vomiting, indigestion, constipation, fatigue, and abdominal cramping, occurred in 18 patients (58%) treated with lisuride and in 17 patients (55%) treated with bromocriptine. And, 3 patients (10%) in the lisuride group and
three
(10%) in the bromocriptine group stopped medication for this reason. There were no significant differences between the lisuride group and the bromocriptine group in the effect of each dopamine agoist on the restoration of menstruation and
fertility
or
its incidence of side effects. These results indicate that lisuride and bromocriptine are comparable in efficacy and side effects. (J Kor Soc Endocrinol 7:8~15, 1992).
|